{"id":685060,"date":"2022-09-14T07:28:51","date_gmt":"2022-09-14T11:28:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/"},"modified":"2022-09-14T07:28:51","modified_gmt":"2022-09-14T11:28:51","slug":"aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/","title":{"rendered":"ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>\n          <strong>ASLAN plans to begin TREK-DX (TRials in <\/strong><br \/>\n          <strong><br \/>\n            <em>EblasaKimab<\/em><br \/>\n          <\/strong><br \/>\n          <strong> in <\/strong><br \/>\n          <strong><br \/>\n            <em>Dupilumab<\/em><br \/>\n          <\/strong><br \/>\n          <strong> eXperienced AD patients) in the fourth quarter of 2022 to evaluate the efficacy and safety of <\/strong><br \/>\n          <strong><br \/>\n            <em>eblasakimab<\/em><br \/>\n          <\/strong><br \/>\n          <strong> as an alternative biologic in atopic dermatitis (AD) patients who have discontinued treatment with <\/strong><br \/>\n          <strong><br \/>\n            <em>dupilumab<\/em><br \/>\n          <\/strong><br \/>\n          \n        <\/li>\n<li>\n          <strong>TREK-DX will study the potential use of <\/strong><br \/>\n          <strong><br \/>\n            <em>eblasakimab<\/em><br \/>\n          <\/strong><br \/>\n          <strong> in patients that have been treated with <\/strong><br \/>\n          <strong><br \/>\n            <em>dupilumab<\/em><br \/>\n          <\/strong><br \/>\n          <strong>, complementing the ongoing TREK-AD trial in biologic na\u00efve patients<\/strong>\n        <\/li>\n<li>\n          <strong>Results from both studies could position <\/strong><br \/>\n          <strong><br \/>\n            <em>eblasakimab<\/em><br \/>\n          <\/strong><br \/>\n          <strong> as the preferred first-choice biologic for the treatment of moderate-to-severe AD<\/strong>\n        <\/li>\n<li>\n          <strong>TREK-DX program is part of the Company\u2019s existing operating plan and has no impact on previously-reported cash runway<\/strong>\n        <\/li>\n<li>\n          <strong>Further discussion of TREK-DX will take place during the Company-hosted R&amp;D Day on September 15, 2022<\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p>MENLO PARK, Calif. and SINGAPORE, Sept.  14, 2022  (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (\u201cASLAN\u201d, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to initiate a new clinical trial of <em>eblasakimab<\/em> for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients who have previously been treated with <em>dupilumab.<\/em><em>Eblasakimab<\/em> is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile. ASLAN expects to enroll the first patient in the trial in the fourth quarter of 2022.<\/p>\n<p>\u201cIn contrast to our Phase 2b trial in biologic na\u00efve patients, TREK-DX will allow us to evaluate <em>eblasakimab<\/em>\u2019s unique mechanism of action in a new patient population,\u201d <strong>said Dr Carl Firth, CEO, ASLAN Pharmaceuticals<\/strong>. \u201cWe believe that many patients previously treated with <em>dupilumab<\/em> can benefit from <em>eblasakimab<\/em>, and this data could support the use of <em>eblasakimab<\/em> in both the biologic na\u00efve and experienced patient populations.\u201d<\/p>\n<p>The TREK-DX trial is expected to enroll 75 patients in a randomized, double-blind, placebo-controlled, multicenter trial in North America to evaluate the efficacy and safety of <em>eblasakimab<\/em> in patients with moderate-to-severe AD previously treated with <em>dupilumab.<\/em> The trial will enroll patients who have discontinued <em>dupilumab<\/em> treatment for any reason, including inadequate control of AD, loss of access or an adverse event. The program is part of the Company\u2019s existing operating plan and has no impact on its previously-reported cash runway.<\/p>\n<p>The trial will consist of a 16-week treatment period and a 12-week safety follow-up period. The primary efficacy endpoint is percentage change in Eczema Area Severity Index (EASI) score from baseline to week 16. Key secondary efficacy endpoints include the proportion of patients achieving Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear), proportion of patients with a 75% or greater reduction in EASI (EASI-75), proportion of patients achieving EASI-50 and EASI-90, and changes in peak pruritus.<\/p>\n<p>\u201c<em>Dupilumab<\/em> has played an important role in demonstrating the benefits of targeting the IL4\/IL-13 signaling pathway in AD. However, some patients do not demonstrate an optimal or sustained response to <em>dupilumab<\/em>, or develop adverse events such as conjunctivitis, and thus seek an alternative treatment option that could offer an improved safety and efficacy profile,\u201d<strong> said Dr Alex Kaoukhov, CMO, ASLAN Pharmaceuticals<\/strong>. \u201cAs we have seen in other indications, such as psoriasis, targeting different molecular components of the same signaling pathway can lead to different clinical outcomes and we believe that <em>eblasakimab\u2019s <\/em>unique approach to blocking the Type 2 receptor may offer an effective treatment for <em>dupilumab<\/em>-experienced patients.\u201d<\/p>\n<p>ASLAN is also conducting the TREK-AD trial, a global randomized, double-blind, placebo-controlled, dose-ranging, Phase 2b clinical trial, to evaluate the efficacy and safety of <em>eblasakimab<\/em> in adult patients with moderate-to-severe AD who are candidates for systemic therapy. Topline data from this trial is expected in the first half of 2023.<\/p>\n<p>ASLAN\u2019s management is hosting a Research and Development (R&amp;D) Day on Thursday, September 15, 2022, from 10:00am to 1:30pm ET at the St. Regis Hotel in New York. To attend the event in person or virtually, please click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_oNQqJpjiyCoF4fYhIrNBivsohD2_JHUlOhnP51g7glZPv83HY-_el3f1bK4w9M33mpH-Rfr2nWCHCBGMQpKRjpB0nz96Fjz2HVbE1gs08lMV4ozkQQSqw2j8Gp42mmg4dIn_yNaAd8TFFFsx8BAQw==\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a> for registration. A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN Pharmaceutical\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ihR_TylBr47BbH9ZcB3qtVlnLb13B5qLgeBCIDQOzDSZUsCLjDTdpFLK6KScIlHEsKivJ0y9tdgzB0Sk9vnwIV6LpWbczepvKCrKtMvn7TE=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ir.aslanpharma.com\/<\/a><\/p>\n<p>\n        <strong>About <\/strong><br \/>\n        <strong><br \/>\n          <em>eblasakimab<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <em>Eblasakimab<\/em> is a novel, potential first-in-class monoclonal antibody that targets the IL-13 receptor \u03b11 subunit (IL13R\u03b11), one of the components of the Type 2 receptor. By blocking the Type 2 receptor, <em>eblasakimab<\/em> prevents signaling through both interleukin 4 (IL-4) and interleukin 13 (IL-13) \u2013 the key drivers of inflammation in AD. Its unique mechanism of action has the potential to deliver a differentiated safety and efficacy profile as well as an improved dosing regimen. ASLAN is currently conducting the TREK-AD trial, a global randomized, double-blind, placebo-controlled, dose-ranging, Phase 2b clinical trial, to evaluate the efficacy and safety of <em>eblasakimab<\/em> in adult patients with moderate-to-severe AD who are candidates for systemic therapy. Topline data is expected in the first half of 2023. The TREK-DX trial evaluating the efficacy and safety of <em>eblasakimab<\/em> in adult patients with moderate-to-severe AD who have previously been treated with <em>dupilumab <\/em>is expected to enroll the first patient in the fourth quarter of 2022.<\/p>\n<p>\n        <strong>About ASLAN Pharmaceuticals<\/strong>\n      <\/p>\n<p>ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN\u00a0is currently evaluating\u00a0<em>eblasakimab<\/em>, a\u00a0potential first-in-class\u00a0antibody\u00a0targeting the IL-13 receptor,\u00a0in atopic dermatitis, and <em>farudodstat<\/em> (also known as ASLAN003),\u00a0a\u00a0potent oral\u00a0inhibitor\u00a0of\u00a0the enzyme DHODH, in autoimmune disease.\u00a0ASLAN has a team in California and in Singapore.\u00a0For additional information please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-o3RVZGp1vVHh2jIwvuB5bXOD4d977nZxDjkd2xz4dlHGxa261Qo8XtqpGom_gjU0Zl6RKHIWUx7yRK5NEXHW-_PAttt7daiNLbbyF_6Q9w=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.aslanpharma.com<\/u><\/a><u>\u00a0<\/u>or follow\u00a0ASLAN\u00a0on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dCOGi9Q7di72hZAWFNz_NGZi0usZj1QSTkNlJDtzse6tJ6tDJ43PRbScmZPIkI208weGj0A335Mo08iO--vp9rmIPoHVK5XEUh1OPku5xCuPNkQdi5cahV42zHwOAmKj3qQ3UKBUZCjwr9vXmzCN0w==\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Forward looking statements <\/strong>\n      <\/p>\n<p>This release contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and\/or its affiliates (the &#8220;Company&#8221;). These forward-looking statements may include, but are not limited to, statements regarding the Company\u2019s business strategy and clinical development plans; the Company\u2019s plans to develop and commercialize <em>eblasakimab<\/em> and <em>farudodstat<\/em>; the safety and efficacy of <em>eblasakimab <\/em>and<em> farudodstat<\/em>; the Company\u2019s plans and expected timing with respect to clinical trials, clinical trial enrolment and clinical trial results for <em>eblasakimab <\/em>and<em> farudodstat<\/em>; the potential of <em>eblasakimab<\/em> as a first-in-class treatment for atopic dermatitis and of <em>farudodstat<\/em> as a treatment for autoimmune disease; and the Company\u2019s cash runway. The Company\u2019s estimates, projections and other forward-looking statements are based on management&#8217;s current assumptions and expectations of future events and trends, which affect or may affect the Company\u2019s business, strategy, operations, or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; clinical site activation rates or clinical trial enrolment rates that are lower than expected; the impact of the COVID-19 pandemic or the ongoing conflict between Ukraine and Russia on the Company\u2019s business and the global economy; general market conditions; changes in the competitive landscape; and the Company\u2019s ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company\u2019s US Securities and Exchange Commission filings and reports (Commission File No. 001- 38475), including the Company\u2019s Annual Report on Form 20-F filed with the US Securities and Exchange Commission on March 25, 2022. All statements other than statements of historical fact are forward-looking statements. The words \u201cbelieve,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201ccould,\u201d \u201cwill,\u201d \u201caim,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cplan,\u201d or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement.<\/p>\n<p>\n        <strong> ASLAN Media and IR contacts<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:37%;width:37%;min-width:37%;vertical-align: top\">\n            <strong>Emma Thompson<\/strong><br \/>\n            <br \/>Spurwing Communications<br \/>Tel: +65 6206 7350 <br \/>Email: <a href=\"mailto:ASLAN@spurwingcomms.com\" rel=\"nofollow noopener\" target=\"_blank\">ASLAN@spurwingcomms.com<\/a><\/td>\n<td style=\"max-width:63%;width:63%;min-width:63%;vertical-align: top\">\n            <strong>Ashley R. Robinson<\/strong><br \/>\n            <br \/>LifeSci Advisors, LLC<br \/>Tel: +1 (617) 430-7577<br \/>Email: <a href=\"mailto:arr@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">arr@lifesciadvisors.com<\/a>\u00a0\u00a0\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjUwNCM1MTUyNjM4IzIwOTU0OTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MGQwNjc3MmEtZGY3Yy00ZDE4LTk2MTEtNTE3YmY3Zjc5ZDU2LTExMDcwNjI=\/tiny\/ASLAN-PHARMACEUTICALS-LIMITED.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ASLAN plans to begin TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) in the fourth quarter of 2022 to evaluate the efficacy and safety of eblasakimab as an alternative biologic in atopic dermatitis (AD) patients who have discontinued treatment with dupilumab TREK-DX will study the potential use of eblasakimab in patients that have been treated with dupilumab , complementing the ongoing TREK-AD trial in biologic na\u00efve patients Results from both studies could position eblasakimab as the preferred first-choice biologic for the treatment of moderate-to-severe AD TREK-DX program is part of the Company\u2019s existing operating plan and has no impact on previously-reported cash runway Further discussion of TREK-DX will take place during the Company-hosted R&amp;D Day on September 15, 2022 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-685060","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ASLAN plans to begin TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) in the fourth quarter of 2022 to evaluate the efficacy and safety of eblasakimab as an alternative biologic in atopic dermatitis (AD) patients who have discontinued treatment with dupilumab TREK-DX will study the potential use of eblasakimab in patients that have been treated with dupilumab , complementing the ongoing TREK-AD trial in biologic na\u00efve patients Results from both studies could position eblasakimab as the preferred first-choice biologic for the treatment of moderate-to-severe AD TREK-DX program is part of the Company\u2019s existing operating plan and has no impact on previously-reported cash runway Further discussion of TREK-DX will take place during the Company-hosted R&amp;D Day on September 15, 2022 &hellip; Continue reading &quot;ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-14T11:28:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjUwNCM1MTUyNjM4IzIwOTU0OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients\",\"datePublished\":\"2022-09-14T11:28:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\\\/\"},\"wordCount\":1343,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NjUwNCM1MTUyNjM4IzIwOTU0OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\\\/\",\"name\":\"ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NjUwNCM1MTUyNjM4IzIwOTU0OTE=\",\"datePublished\":\"2022-09-14T11:28:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NjUwNCM1MTUyNjM4IzIwOTU0OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NjUwNCM1MTUyNjM4IzIwOTU0OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/","og_locale":"en_US","og_type":"article","og_title":"ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients - Market Newsdesk","og_description":"ASLAN plans to begin TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) in the fourth quarter of 2022 to evaluate the efficacy and safety of eblasakimab as an alternative biologic in atopic dermatitis (AD) patients who have discontinued treatment with dupilumab TREK-DX will study the potential use of eblasakimab in patients that have been treated with dupilumab , complementing the ongoing TREK-AD trial in biologic na\u00efve patients Results from both studies could position eblasakimab as the preferred first-choice biologic for the treatment of moderate-to-severe AD TREK-DX program is part of the Company\u2019s existing operating plan and has no impact on previously-reported cash runway Further discussion of TREK-DX will take place during the Company-hosted R&amp;D Day on September 15, 2022 &hellip; Continue reading \"ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-14T11:28:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjUwNCM1MTUyNjM4IzIwOTU0OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients","datePublished":"2022-09-14T11:28:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/"},"wordCount":1343,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjUwNCM1MTUyNjM4IzIwOTU0OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/","name":"ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjUwNCM1MTUyNjM4IzIwOTU0OTE=","datePublished":"2022-09-14T11:28:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjUwNCM1MTUyNjM4IzIwOTU0OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjUwNCM1MTUyNjM4IzIwOTU0OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-commences-clinical-program-to-study-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/685060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=685060"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/685060\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=685060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=685060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=685060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}